Back to All Combinations

Acquired RAS (Post-Anti-EGFR)

Intermediate Prognosis
30.00% Prevalence Level 2A Resistance Mechanisms
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
KRAS NRAS
Treatment Implications

RAS clones may decline after withdrawal. Rechallenge possible.

Recommended Treatments
Chemo holiday from anti-EGFR
Liquid biopsy monitoring
Anti-EGFR rechallenge
Treatments to Avoid
Continuing anti-EGFR
Study References

CHRONOS trial

Key Statistics
30.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Clonal evolution is reversible.
Information

Category: Resistance Mechanisms

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.